678 related articles for article (PubMed ID: 32130661)
1. Efficacy and Safety of Basal Insulin-Based Treatment Versus Twice-Daily Premixed Insulin After Short-Term Intensive Insulin Therapy in Patients with Type 2 Diabetes Mellitus in China: Study Protocol for a Randomized Controlled Trial (BEYOND V).
Liu J; Jiang X; Xu B; Wang G; Cui N; Zhang X; Liu J; Mu Y; Guo L
Adv Ther; 2020 Apr; 37(4):1675-1687. PubMed ID: 32130661
[TBL] [Abstract][Full Text] [Related]
2. Randomized, open-label, parallel-group evaluations of basal-bolus therapy versus insulin lispro premixed therapy in patients with type 2 diabetes mellitus failing to achieve control with starter insulin treatment and continuing oral antihyperglycemic drugs: a noninferiority intensification substudy of the DURABLE trial.
Miser WF; Arakaki R; Jiang H; Scism-Bacon J; Anderson PW; Fahrbach JL
Clin Ther; 2010 May; 32(5):896-908. PubMed ID: 20685497
[TBL] [Abstract][Full Text] [Related]
3. Combination of oral antidiabetic agents with basal insulin versus premixed insulin alone in randomized elderly patients with type 2 diabetes mellitus.
Janka HU; Plewe G; Busch K
J Am Geriatr Soc; 2007 Feb; 55(2):182-8. PubMed ID: 17302653
[TBL] [Abstract][Full Text] [Related]
4. Comparison of biphasic insulin aspart 30 given three times daily or twice daily in combination with metformin versus oral antidiabetic drugs alone in patients with poorly controlled type 2 diabetes: a 16-week, randomized, open-label, parallel-group trial conducted in russia.
Ushakova O; Sokolovskaya V; Morozova A; Valeeva F; Zanozina O; Sazonova O; Zhadanova E; Starceva M; Kazakova E; Saifullina M; Shapiro I; Tarasov A; Al-Tayar B; Starkova N
Clin Ther; 2007 Nov; 29(11):2374-84. PubMed ID: 18158078
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and treatment satisfaction of once-daily insulin glargine plus one or two oral antidiabetic agents versus continuing premixed human insulin in patients with type 2 diabetes previously on long-term conventional insulin therapy: the Switch pilot study.
Schiel R; Müller UA
Exp Clin Endocrinol Diabetes; 2007 Nov; 115(10):627-33. PubMed ID: 18058596
[TBL] [Abstract][Full Text] [Related]
6. Comparison of basal insulin added to oral agents versus twice-daily premixed insulin as initial insulin therapy for type 2 diabetes.
Janka HU; Plewe G; Riddle MC; Kliebe-Frisch C; Schweitzer MA; Yki-Järvinen H
Diabetes Care; 2005 Feb; 28(2):254-9. PubMed ID: 15677775
[TBL] [Abstract][Full Text] [Related]
7. A 52-week, multinational, open-label, parallel-group, noninferiority, treat-to-target trial comparing insulin detemir with insulin glargine in a basal-bolus regimen with mealtime insulin aspart in patients with type 2 diabetes.
Hollander P; Cooper J; Bregnhøj J; Pedersen CB
Clin Ther; 2008 Nov; 30(11):1976-87. PubMed ID: 19108786
[TBL] [Abstract][Full Text] [Related]
8. Glycemic control and safety in Chinese patients with type 2 diabetes mellitus who switched from premixed insulin to insulin glargine plus oral antidiabetics: a large, prospective, observational study.
Zhang B; Zhao J; Yang W;
Diabetes Metab Res Rev; 2017 Mar; 33(3):. PubMed ID: 27667797
[TBL] [Abstract][Full Text] [Related]
9. Glycemic control with insulin glargine plus insulin glulisine versus premixed insulin analogues in real-world practices: a cost-effectiveness study with a randomized pragmatic trial design.
Levin PA; Zhang Q; Mersey JH; Lee FY; Bromberger LA; Bhushan M; Bhushan R
Clin Ther; 2011 Jul; 33(7):841-50. PubMed ID: 21719107
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of a basal insulin + 2-3 oral antihyperglycaemic drugs regimen versus a twice-daily premixed insulin + metformin regimen after short-term intensive insulin therapy in individuals with type 2 diabetes: The multicentre, open-label, randomized controlled BEYOND-V trial.
Pan Q; Li Y; Wan H; Wang J; Xu B; Wang G; Jiang C; Liang L; Feng W; Liu J; Wang T; Zhang X; Cui N; Mu Y; Guo L;
Diabetes Obes Metab; 2022 Oct; 24(10):1957-1966. PubMed ID: 35642463
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and treatment satisfaction of once-daily insulin glargine plus one or two oral antidiabetic agents versus continuing premixed human insulin in patients with Type 2 diabetes previously on long-term conventional insulin therapy: the SWITCH Pilot Study.
Schiel R; Müller UA
Exp Clin Endocrinol Diabetes; 2008 Jan; 116(1):58-64. PubMed ID: 17973208
[TBL] [Abstract][Full Text] [Related]
12. Influence of baseline glycemia on outcomes with insulin glargine use in patients uncontrolled on oral agents.
Banerji MA; Baron MA; Gao L; Blonde L
Postgrad Med; 2014 May; 126(3):111-25. PubMed ID: 24918797
[TBL] [Abstract][Full Text] [Related]
13. Comparison of thrice-daily premixed insulin (insulin lispro premix) with basal-bolus (insulin glargine once-daily plus thrice-daily prandial insulin lispro) therapy in east Asian patients with type 2 diabetes insufficiently controlled with twice-daily premixed insulin: an open-label, randomised, controlled trial.
Jia W; Xiao X; Ji Q; Ahn KJ; Chuang LM; Bao Y; Pang C; Chen L; Gao F; Tu Y; Li P; Yang J
Lancet Diabetes Endocrinol; 2015 Apr; 3(4):254-62. PubMed ID: 25754414
[TBL] [Abstract][Full Text] [Related]
14. A comparison of twice-daily biphasic insulin aspart 70/30 and once-daily insulin glargine in persons with type 2 diabetes mellitus inadequately controlled on basal insulin and oral therapy: a randomized, open-label study.
Ligthelm RJ; Gylvin T; DeLuzio T; Raskin P
Endocr Pract; 2011; 17(1):41-50. PubMed ID: 20713345
[TBL] [Abstract][Full Text] [Related]
15. Insulin glargine-based therapy improves glycemic control in patients with type 2 diabetes sub-optimally controlled on premixed insulin therapies.
Davies M; Sinnassamy P; Storms F; Gomis R;
Diabetes Res Clin Pract; 2008 Feb; 79(2):368-75. PubMed ID: 17980928
[TBL] [Abstract][Full Text] [Related]
16. A Multinational, Randomized, Open-label, Treat-to-Target Trial Comparing Insulin Degludec and Insulin Glargine in Insulin-Naïve Patients with Type 2 Diabetes Mellitus.
Pan C; Gross JL; Yang W; Lv X; Sun L; Hansen CT; Xu H; Wagner R
Drugs R D; 2016 Jun; 16(2):239-49. PubMed ID: 27098525
[TBL] [Abstract][Full Text] [Related]
17. Prandial Options to Advance Basal Insulin Glargine Therapy: Testing Lixisenatide Plus Basal Insulin Versus Insulin Glulisine Either as Basal-Plus or Basal-Bolus in Type 2 Diabetes: The GetGoal Duo-2 Trial.
Rosenstock J; Guerci B; Hanefeld M; Gentile S; Aronson R; Tinahones FJ; Roy-Duval C; Souhami E; Wardecki M; Ye J; Perfetti R; Heller S;
Diabetes Care; 2016 Aug; 39(8):1318-28. PubMed ID: 27222510
[TBL] [Abstract][Full Text] [Related]
18. [Post-hoc analyses of type 2 diabetes patients switch from premixed insulin regimen to basal insulin plus oral hypoglycemic agents regimen].
Bu S; Guo XH; Yang WY; Lu GZ; Yang ZJ; Ren TT; Gao Y
Zhonghua Yi Xue Za Zhi; 2007 Nov; 87(44):3115-8. PubMed ID: 18269868
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and risk of hypoglycemia with use of insulin glargine or comparators in patients with cardiovascular risk factors.
Blonde L; Baron MA; Zhou R; Banerji MA
Postgrad Med; 2014 May; 126(3):172-89. PubMed ID: 24918802
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of metformin-based oral antidiabetic drugs is not inferior to insulin glargine in newly diagnosed type 2 diabetic patients with severe hyperglycemia after short-term intensive insulin therapy.
Cheng Q; Yang S; Zhao C; Wang Z; Feng Z; Li R; Ye P; Zhang S; Deng H; Zhou B; Long J; Gong L; Qing H; Luo C; Li Q
J Diabetes; 2015 Mar; 7(2):182-91. PubMed ID: 24823280
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
